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Arapid, selectiveandsensitive liquid chromatographyetandemmass spectrometry (LCeMS/
MS) method has been developed and validated for the determination of pitavastatin in
humanplasma. Followinga liquideliquid extraction, both theanalytes and internal standard
telmisartan were separated on a Luna C18 column with a mobile phase consisted of aceto-
nitrileemethanole1% formic acid in water (50:25:25, v/v/v). Mass spectrometric detection
involved electrospray ionization in the positive ion mode followed by multiple reaction
monitoring (MRM) of the transitions at m/z 421.9 / 290.1 for pitavastatin and m/z
515.2/ 276.2 for the IS. The assay for pitavastatin showed good linearity (r  0.99) over the
ranges 0.2e400 ng/ml,with a lower limit of quantitation of 0.2 ng/ml. Accuracy and precision
for the assay were determined by calculating the intra- and inter-batch variation of quality
control (QC) samples at three concentration levels, with relative standard deviations (RSD) of
less than 15% for both analytes. The mean extraction recovery of pitavastatin and IS were
both above 70%. Matrix effect hasn't been found in this method. The method has been suc-
cessfully applied to a clinic pharmacokinetic study of pitavastatin administered.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitors (statins) inhibit the synthesis of mevalonate, a
ratelimiting step in cholesterol level. Competitive inhibition
of HMG-CoA reductase by the statins decreases hepatocytetical University, No. 103
d2013@163.com (Q. Liu).
g Pharmaceutical Univer
University. Production an
ns.org/licenses/by-nc-ndcholesterol synthesis, which results in increased extraction of
LDL-C from the blood and decrease circulating LDL-C concen-
trations [1]. High plasma LDL-cholesterol is a risk factor of
cardiovascular diseases and, therefore, cholesterol-lowering
drugs are used to prevent them. Some randomized controlled
trialshaveshownthat statinshavepotentcholesterol-lowering, Wenhua Road, Shenyang 110016, China. Tel.: þ86 24 23986298,
sity.
d hosting by Elsevier B.V. This is an open access article under the
/3.0/).
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everydaymedical practice [2e5].
Pitavastatin (NK-104, previously called itavastatin or nis-
vastatin) is a novel, fully synthetic statin with the chemical
name of (þ)-monocalcium bis(3R,5S,6E)-7-[2-cyclopropyl-4-(4-
fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate
(C50H46CaF2N2O8) [6,7]. It can reduce plasma level of LDL-
cholesterol by 40% in hypercholesterolaemic patients [8]. Pit-
avastatin has been launched in Japan, and is becoming
available in Europe, the US, and Asia. Normal-phase HPLC
with UV detection was described by Kojima et al., with a LLOQ
of 0.5 ng/ml achieved [9]. However, the chromatographic run
time for one sample was relatively long(25 min). Hui et al. [10]
used abovemethod and achieved a LLOQ of 1.0 ng/ml. Lv et al.
[11] established an HPLCeMS/MS method with liquideliquid
extraction(LLE) to determine pitavastatin in human plasma,
with a LLOQ of 0.2 ng/ml. The need to better characterize the
clinical pharmacokinetic properties of pitavastatin compelled
us to set up and validate a simple, specific and sensitive
analyticalmethod. In this study, a technique based on LCeMS/
MS intended for the determination of pitavastatin was
developed and validated, with a LLOQ of 0.2 ng/ml and shorter
chromatographic cycle time(2.1 min). This method was suc-
cessfully applied to clinical pharmacokinetic study among
Chinese people.Fig. 1 e Production scan of (A) pitavastatin and (B)
telmisartan.2. Materials and methods
2.1. Chemicals and reagents
Pitavastatin calciumwere supplied byQiduCompany Ltd., and
telmisartan (internal standard, IS) were from the National
Institute for the Control of Pharmaceutical and Biological
Products (Beijing, China). The purity of the two chemicalswere
99.7%, 99.3%, respectively. HPLC grade methanol, acetonitrile,
amino acid and ammonium acetate (purity: 99.5%) were all
obtained from Dikma (Beijing, China). All other chemicals and
reagents were of analytical grade and were used without any
further purification.
2.2. Instrumentation
An Agilent 1100 system (Agilent, USA) consisting of a vacuum
degasser (G1379A), a quaternary pump (G1311A), a column
oven (G1316A) and an autosampler (G1313A) was used for
solvent and sample delivery. An Applied Biosystems API 2000
triple-quadrupole mass spectrometer equipped with a Turbo
IonSpray ionization (ESI) source was used for mass spectral
analysis and the system was operated in positive mode. Data
acquisition was performed with Analyst 1.4.1 software
(Applied Biosystems, USA). Peak integration and calibration
were carried out using SPSS 11.5 software (SPSS Inc., USA).
2.3. Operating conditions
Separations of analytes were achieved using a Luna C18 col-
umn (50 mm  2.0 mm, 5 mm) protected by a Security guard
(Waters, Inc.), eluting isocratically at 0.25 ml/min with a mo-
bile phase of acetonitrileemethanole0.1% formic acid(50:25:25, v/v/v). The run time of one sample was about
2.1 min. In order to assure the repeatability of retention time,
the column temperature was controlled at 20 C. The opti-
mized TurboIonSpray voltage and temperature were set at
5000 V and 400 C, respectively. The source parameters, viz.
the nebulizer gas, curtain gas, auxiliary gas and collision gas
were set at 60, 20, 70 and 5 psi, respectively. The compound
parameters viz. the declustering potential (DP), collision en-
ergy (CE), entrance potential (EP) and collision cell exit po-
tential (CXP) were 60, 42, 8, 6 eV and 80, 70, 10, 5 eV for the IS.
Based on the full-scan MS and MS/MS spectra of the drug, the
most abundant fragment ion was selected and the mass
spectrometer was set tomonitor the transitionm/z 421.9/m/
z 290.1 for pitavastatin and m/z 515.2 / m/z 276.2 for IS,
respectively. The production scan of pitavastatin and telmi-
sartanwas shown in Fig. 1. The scan time for each analytewas
set to 0.2 s.
2.4. Drug administration and sample collection
An open-label, randomized study was conducted in Phase I
Clinical Research Institute of the Beijing Military General
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mittee(IEC) of Beijing Military General Hospital approved the
protocol and the volunteers were provided with informed
written consent. Thirty healthy Chinese volunteers (15 fe-
males and 15 males) were chosen to attend the study. The
volunteers aged between 23 to 33 y and their IBM figures were
between 19 and 24. Subjects were randomized into one of
three groups (10 subjects/group) to be given a single dose of 1,
2 and 4 mg pitavastatin per day. Blood samples were collected
at pre-dose and 0.17, 0.33, 0.5 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24 and
48 h, in heparin vacutainer collection tubes. The tubes were
centrifuged at 3000 r/min for 10 min and the plasma was
collected. The collected plasma samples were stored at 70 C
till their use. The 2 mg group then completed a 7-day washout
period. Beginning on the morning of day 8, subjects received
2 mg of pitavastatin once daily for a total of 7 doses.2.5. Preparation of stock solutions of analytes and IS
The stock solutions of pitavastatin (100 mg/ml) and the IS
(100 mg/ml) were separately prepared in methanol. Serial di-
lutions were prepared with methanol at concentrations of
2000, 1000, 500, 100, 50, 10, 5, 2.5 and 1 ng/ml for pitavastatin,
respectively. Working solutions of IS were prepared by further
diluting the IS stock solutions with methanol at concentra-
tions of 1 mg/ml and 50 ng/ml. All the working standard solu-
tions were stored at 4 C; they were found to be stable for 8 d.2.6. Preparation of calibration curves and quality control
samples
Calibration samples were prepared by spiking 250 ml of control
human plasma with 50 ml working standard solution of the
analyte, to produce the matrix-matched calibration standards
at concentrations of 0.2, 1.0, 2.0, 10.0, 20.0, 100.0, 200.0,
400.0 ng/ml of pitavastatin. Each sample also contained 50 ml
IS solutions(50 ng/ml). In each calibration run a plasma blank
sample (no IS) was also analyzed.
The QC samples of three different concentration levels (0.5,
20, 320 ng/ml) were selected to cover the entire range of cali-
brations. They were prepared daily by spiking 250 ml plasma
samples with appropriate volumes of a standard solution to
produce the stated final concentration of pitavastatin and
50 ng/ml of the IS.2.7. Sample preparation
QC samples, calibration standards, and clinical plasma sam-
ples were extracted employing a LLE technique. To each tube
containing 250 ml plasma, 50 ml of the 50 ng/ml of the IS, and
100 ml of 0.05 mol/l phosphoric acid, vortexed for 1 min, then
2 ml of a mixture of ether: dichloromethane (4:1, v/v) were
added, and the mixture was then vortexed for 10 min. The
samples were then centrifuged for 5 min at 10,000 r/min.
1.5 ml of the organic layer was transferred to another clean
tube and was evaporated to dryness at 38 C under a gentle
stream of nitrogen. The residue was dissolved in 100 ml of themobile phase, and a 15 ml aliquot was injected onto the
LCeMS/MS system for analysis.2.8. Mehtod validation
The analytical procedure was validated in terms of speci-
ficity, sensitivity, linearity, precision and accuracy, extrac-
ition recovery, matrix effect and stability. Specificy of the
method was assessed by analyzing six blank human plasma
matrix samples. The responses of the interfering substances
or background noises at the retention time of the pit-
avastatin are acceptable if they are less than 20% of the
response of the lowest standard curve point or LLOQ. The
responses of the interfering substances or background noise
at the retention time of the internal standard are acceptable
if they are less than 5% of the response of the workinig in-
ternal standard.
Calibration curves for each analyte were individually con-
structed by least-squares linear regression analysis of an
eightpoint calibration curve by plotting analyte-to-IS peak
area ratio versus its nominal concentration, using 1/x2 as a
weighting factor. Sensitivity was established from the back-
ground noise or response from six spiked LLOQ samples. The
six replicates should have a precision of 20% and an accu-
racy of ±20%.
The intra-day accuracy and precision were evaluated
by analyzing six replicates at three QC concentration levels
for human plasma samples on the same day. The inter-day
assay accuracy and precision were determined by
analyzing the three-level QC samples on three runs in three
consecutive d. The criteria for acceptability of the data
included accuracy within ±15% deviation from the nominal
values and a precision of within 15% relative standard de-
viation (RSD), except at the LLOQ, where it should not exceed
±20%.
Extraction recovery and matrix effect were evaluated at
three concentration levels (LQC, MQC and HQC) for each
analyte and at the working concentration for internal stan-
dards. Post-spiked QCs used in recovery and matrix effect
test, were prepared by spiking the extracted bland matrix
with analyte and IS to ensure that concentrations are
equivalent to those in the LQC, MQC and HQC extracted
samples. Extraction recovery was calculated by comparing
the signal of analyte or IS of regular QCs with those of post-
spiked QCs. Matrix effect was evaluated by comparing the
signal of post-spiked QCs with those of the neat solutions at
LQC, MQC and HQC levels.
Stability tests were conducted to evaluate the analyte
stability in stock solutions and in plasma samples under
different conditions. The stock solution stability at refriger-
ated conditions (4 C) was performed by comparing the area
response of the analytes (stability samples) with the
response of the sample prepared from fresh stock solution.
Bench top stability (2 h), processed samples stability (room
temperature for 8 h), freeze-thaw stability (two cycles), and
long-term stability (20 d) were performed at LQC, MQC and
HQC levels using three replicates at each level. Samples were
considered to be stable if assay values were within
Fig. 2 e Typical MRM chromatograms of pitavastatin (left panel) and IS (right panel) in (A) human blank plasma, and (B)
human plasma spiked with IS, and (C) a plasma sample from a volunteer 3.0 h after oral administration of 1 mg pitavastatin.
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Table 1 e Intra-day and inter-day precision and accuracy for pitavastatin.
Analyte QC(spiked concentration ng/ml) Intra-day (n ¼ 18) Inter-day (n ¼ 18)
Mean
concentration
(ng/ml)
Precision
(RSD,%)
Accuracy (%) Mean
concentration
(ng/ml)
Precision
(RSD,%)
Accuracy (%)
Pitavastatin 0.5 (LQC) 0.51 ± 8.84 8.84 102.0 0.51 ± 5.13 5.13 102.0
20.0 (MQC) 19.4 ± 5.41 5.41 97.2 20.5 ± 11.8 11.8 102.6
320.0 (HQC) 314.5 ± 7.08 7.08 98.3 321 ± 8.41 8.41 100.4
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(15% RSD).3. Results and discussion
3.1. Mass spectrometry and chromatography conditions
The objective of the present work was to develop and fully
validate a LCeMS/MS method for the determination of pit-
avastatin in human plasma. To realize this aim, the extraction
procedure, mass spectrometry and chromatographic condi-
tions were optimized. Due to the alkaline nitrogen atom on
the pyridine cycle in the molecular structure, the positive
ionization mode should be more appropriate for pitavastatin
than the negative mode. The mass spectrograms of pit-
avastatin and the internal standard telmisartan exhibited a
protonated molecular ion at m/z 421.9 and 515.2, respectively.
The high collision energy gave themost abundant product ion
at m/z 290.1 and 276.2 for pitavastatin and telmisartan,
respectively. Therefore, the precursor to product transition
was assigned in the selected reaction monitor mode as fol-
lows: m/z 421.9 / m/z 290.1 for pitavastatin and m/z
515.2 / m/z 276.2 for telmisartan. In order to obtain the
highest sensitivity, the mass spectrometry parameters were
optimized by the auto-tuning. To attain an ideal Taylor cone
and a better impact on spectral response, the nebulizer gas
(gas 1) pressure was optimized at 60 psi. The ion transfer
capillary temperature was set at 400 C. The ion spray voltage
was 5000 V. Collision energies were set at 42 and 70 V for
pitavastatin and telmisartan (IS), respectively. The unit reso-
lution was set for both Q1 and Q3 mass detection.
To optimize chromatographic conditions and obtain
shorter run time, different methanol and acetonitrile ratios
had been tried, 25% methanol and 50% acetonitrile was suit-
able for determination of the analytes. The high organic sol-
vent content shortened the chromatographic cycle time and
the acid modifier, formic acid, improved the signal intensity
greatly. Therefore, the mixture of acetonitrile, methanol andTable 2 e Absolute recoveries and matrix effect of pitavastatin
Analyte QC(spiked concentration, ng/ml)
Pitavastatin 0.5 (LQC)
20.0 (MQC)
320.0 (HQC)
Telmisartan 50 (IS)1% formic acid (50:25:25, v/v/v) was finally used as mobile
phase. A flow rate of 0.25 ml/min permitted a run time of
2.1 min.
3.2. Method validation
3.2.1. Selectivity
The degree of interference by endogenous plasma constitu-
ents with the analytes and IS was assessed by inspection of
chromatograms derived from processed blank plasma sam-
ple. As shown in Fig. 2, no significant direct interference in the
blank plasma traces was observed from endogenous sub-
stances in drug-free plasma at the rentention time of the
analytes.
3.2.2. Linearity, sensitivity, accuracy and precision
The method exhibited good linear response for the concen-
tration range 0.2e400 ng/ml with correlation coefficients of
0.9974. The linear equation for the concentration vs. the peak
area was y ¼ 0.0641x þ 0.00826 where y is analyte/IS peak area
ratio and x is analyte concentration. The LLOQ for pitavastatin
was found to be 0.2 ng/ml. Three concentrations of QC sam-
ples were analyzed to determine the accuracy and precision of
the assay. Precision and accuracy data for intra- and inter-day
plasma samples were presented in Table 1. The accuracy
expressed as bias and precision expressed as RSD were all
found to be within the criteria limit.
3.2.3. Recovery and matrix effects
The recoveries, matrix effects for pitavastatin and IS are pre-
sented in Table 2. The mean extraction recoveries for pit-
avastatin were 79.9 ± 8.23%, 71.5 ± 13.9% and 74.4 ± 6.35% at
concentrations of 0.5, 20 and 320 ng/ml, respectively. The
mean extraction recoveries of the IS were 76.5 ± 12.8% at
concentrations of 50 ng/ml. Matrix interferences caused by
plasma were evaluated by comparing the peak areas of the
post-spiked standards with those of the neat standard at the
QC concentrations. In this study, the matrix effects of the
analytes were 104.3 ± 11.4%, 102.8 ± 7.73% and 100.7 ± 8.41% atand telmisartan (IS) in human plasma.
Recovery (n ¼ 18)
Mean value (%)
Matrix effect (n ¼ 9)
Mean value (%)
79.9 ± 8.23 104.3 ± 11.4
71.5 ± 13.9 102.8 ± 7.73
74.4 ± 6.35 100.7 ± 8.41
76.5 ± 12.8 98.9 ± 4.57
Table 3 e Stability samples result for pitavastatin in
human plasma.
Stability test QC (spiked
concentration,
ng/ml)
Mean
concentration
found (ng/ml)
Pre-preparative
stability 2 h at
room temperature
0.5 (LQC) 0.47 ± 8.69
20.0 (MQC) 18.8 ± 7.25
320.0 (HQC) 303 ± 10.8
Post-preparative
stability 8 h
at room temperature
0.5 (LQC) 0.54 ± 3.47
20.0 (MQC) 19.4 ± 1.19
320.0 (HQC) 344 ± 4.80
Freeze and thaw stability
2 cycles at 20 C
0.5 (LQC) 0.52 ± 3.69
20.0 (MQC) 18.6 ± 4.99
320.0 (HQC) 343 ± 3.65
Long-term stability
20 d at 20 C
0.5 (LQC) 0.49 ± 8.29
20.0 (MQC) 20.1 ± 1.79
320.0 (HQC) 301 ± 2.34
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matrix effect of the IS were 98.9 ± 4.57% at concentrations of
50 ng/ml. The results indicates that the plasma extract did not
cause significant ionization suppression or enhancement for
both analytes and IS in different lots of plasma.
3.2.4. Stability
QC samples were subjected to short-term room temperature
conditions, long-term storage conditions (20 C), and two
freeze-thaw recycles. All the stability studies were conducted
at three concentration levels with three determinations for
each. The stability experiment confirmed that samples were
stable over 20 d when stored at 20 C and through 2 freeze-
thaw cycles. The plasma samples were stable for at least 2 h
pre-preparation and 8 h post-preparation at room tempera-
ture. Detail stability data are shown in Table 3.0 12
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Fig. 3 e Mean plasma concentrationetime curve of pitavastatin
(n ¼ 10).3.3. PK study
The validated LC/MS/MS method was successfully applied in
Phase I clinical pharmacokinetic study to quantify the pit-
avastatin concentration in plasma which were collected from
Chinese volunteers after the administration of a single oral
dose of 1, 2 and 4 mg pitavastatin and a multiple dose of 2 mg
pitavastatin followed. Profiles of the mean plasma concen-
trationetime curves after administration at three single
dosage levels and multiple dosage level of 2 mg are presented
in Figs. 3 and 4. The main pharmacokinetic parameters are
listed in Table 4.
The pharmacokinetics results showed that plasma Cmax
values of pitavastatin at three single dosage levels were
27.8 ± 9.11, 51.5 ± 15.0 and 108 ± 45.5 ng/ml, respectively. The
absorption of pitavastatin was rapid, with t1/2 occurring
0.65 ± 0.17, 0.81 ± 0.34 and 0.88 ± 0.18 h, respectively. The area
under the curve (AUC) were found to be 82.5 ± 32.2, 146 ± 39.2
and 272 ± 102 ng h/ml, respectively. After the administration
of a single dose 2 mg pitavastatin, the Cmax and AUC were
62.5 ng/ml and 207.4 ng h/ml in another study in Chinese [12],
which is similar with the results of this study. However, the
results of this study were different from another study in
Japanese volunteers, in which Cmax and AUC were found to
be 26.1 ng/ml and 58.8 ng h/ml, respectively [9]. We assume
that this is caused by the individual difference among the
subjects who participated in the trials. In this study,
Comparing by single-factor analysis of variance, no signifi-
cant differences were found among the following pharma-
cokinetic parameters: t1/2, MRT0e48h, MRT0e∞, CL/F and Vd/F
after a single oral administration of pitavastatin at three
dosage levels. The linearities between pharmacokinetic pa-
rameters (Cmax, AUC0e48h and AUC0e∞) and dosage levels
were good (correlation coefficient r > 0.99), suggesting linear
pharmacokinetics.24 36 48
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Fig. 4 e Mean plasma concentrationetime curve of pitavastatin at single dose and multiple dose of 2 mg of administration
(n ¼ 10).
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were administered a multiple dosage for seven d (Table 5)
showed that the t1/2, AUC0e48h, AUC0e∞, Cmax, MRT0e48h,
MRT0e∞, CL/F and Vd/F values of single dosage of 2 mg and
multiple dosage of 2 mg have no difference (P > 0.05). The
accumulation factor (Rac) of pitavastatin was 0.98 ± 0.30
showing that no drug accumulation was observed in the body.Table 5 e Pharmacokinetic parameters of pitavastatin
following single dose and multiple dose of 2 mg4. Conclusion
A sensitive, specific, rapid and costless LCeMS/MSmethod for
analysis of pitavastatin in human plasma has been developed
and validated. Simple liquideliquid extraction sample prepa-
ration procedure and chromatography analysis were used inTable 4 e Pharmacokinetic parameters of pitavastatin
following single dose of 1, 2 and 4 mg, respectively
(Mean ± SD, n ¼ 10).
Parameters 1 mg-dose 2 mg-dose 4 mg-dose
Tmax (h) 0.65 ± 0.17 0.81 ± 0.34 0.88 ± 0.18
Cmax (ng/ml) 27.8 ± 9.11 51.5 ± 15.0 108 ± 45.5
Ke (h
1) 0.083 ± 0.068 0.068 ± 0.043 0.056 ± 0.015
t1/2 (h) 13.2 ± 7.02 12.8 ± 5.40 13.4 ± 3.76
AUC0e48h (ng/ml h) 82.5 ± 32.2 146 ± 39.2 272 ± 102
AUC0e∞ (ng/ml h) 89.5 ± 35.9 155 ± 41.9 287 ± 105
MRT(0e48h) (h) 8.55 ± 2.85 7.80 ± 2.29 7.69 ± 1.61
MRT(0e∞) (h) 13.5 ± 5.45 11.7 ± 4.05 10.9 ± 3.11
CL/F (l/h) 12.9 ± 5.02 13.6 ± 2.97 15.7 ± 5.86
Vd/F (l) 218 ± 130 253 ± 124 292 ± 107the method. The method has a lower limit of quantitation of
0.2 ng/ml and the chromatographic cycle time (2.1 min) is
shorter than the reported method. Our method allowed high-
throughput analysis with minimal matrix interference and
has been shown to be successfully applied to phase I phar-
macokinetic studies in healthy subjects. In this work we have
studied the effect of multiple dosage (2 mg) of pitavastatin in
human bodies which showed there was no significant accu-
mulation. The sensitive and specific method was suitable for
analysis of the large batches of sample.(Mean ± SD, n ¼ 10).
Parameters 2 mg (single dose) 2 mg (multiple dose)
Tmax (h) 0.81 ± 0.34 0.80 ± 0.48
Cssmax (ng/ml) 51.5 ± 15.0 48.5 ± 23.2
Cssmin (ng/ml) e 1.17 ± 0.43
Cssav (ng/ml) e 5.05 ± 1.05
Ke (h
1) 0.068 ± 0.043 0.075 ± 0.038
t1/2 (h) 12.8 ± 5.40 11.2 ± 4.93
AUCss (ng/ml h) e 121 ± 25.3
AUC0e48h (ng h/ml) 146 ± 39.2 139 ± 31.4
AUC0e∞ (ng/ml h) 155 ± 41.9 146 ± 31.3
MRT0e48h (h) 7.80 ± 2.29 8.52 ± 2.32
MRT0e∞ (h) 11.7 ± 4.05 12.3 ± 4.12
CL/F (l/h) 13.6 ± 2.97 14.3 ± 3.06
Vd/F (l) 253 ± 124 232 ± 116
DF e 9.19 ± 3.05
Rac e 0.98 ± 0.30
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